Targeting Tumor-Associated Macrophages in Cancer Immunotherapy

被引:51
作者
Petty, Amy J. [1 ]
Owen, Dwight H. [2 ,3 ]
Yang, Yiping [3 ,4 ]
Huang, Xiaopei [3 ,4 ]
机构
[1] Duke Univ, Dept Med, Med Ctr, Durham, NC 27710 USA
[2] Ohio State Univ, Div Med Oncol, Dept Internal Med, Coll Med, Columbus, OH 43210 USA
[3] Ohio State Univ, OSU Comprehens Canc Ctr, Columbus, OH 43210 USA
[4] Ohio State Univ, Div Hematol, Dept Internal Med, Coll Med, Columbus, OH 43210 USA
关键词
tumor-associated macrophages (TAM); tumor microenvironment; immunotherapy; checkpoint inhibitor; cancer; REGULATORY T-CELLS; CHEMOKINE LIGAND 2; EPITHELIAL-MESENCHYMAL TRANSITION; HUMAN MONOCLONAL-ANTIBODY; ENDOTHELIAL GROWTH-FACTOR; CARLUMAB CNTO 888; PANCREATIC-CANCER; OPEN-LABEL; ANGIOGENIC SWITCH; IMMUNE PRIVILEGE;
D O I
10.3390/cancers13215318
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary: Tumor-associated macrophages (TAMs) coinhabit the tumor microenvironment with cancer, immune, and stromal cells. They undermine the immune system and facilitate tumor growth and metastasis. In this review, we discussed current understanding of TAMs functions, and strategies harnessing the knowledge gained from recent research to develop innovative cancer treatments. We summarized pre-clinical/clinical studies targeting TAMs with small molecule inhibitors or antibodies alone or combined with chemotherapy/immunotherapy, evaluated the efficacy of these therapies, and discussed mechanisms of actions.Tumor-associated macrophages (TAMs) represent the most abundant leukocyte population in most solid tumors and are greatly influenced by the tumor microenvironment. More importantly, these macrophages can promote tumor growth and metastasis through interactions with other cell populations within the tumor milieu and have been associated with poor outcomes in multiple tumors. In this review, we examine how the tumor microenvironment facilitates the polarization of TAMs. Additionally, we evaluate the mechanisms by which TAMs promote tumor angiogenesis, induce tumor invasion and metastasis, enhance chemotherapeutic resistance, and foster immune evasion. Lastly, we focus on therapeutic strategies that target TAMs in the treatments of cancer, including reducing monocyte recruitment, depleting or reprogramming TAMs, and targeting inhibitory molecules to increase TAM-mediated phagocytosis.
引用
收藏
页数:19
相关论文
共 151 条
[81]   Tumor-Associated Macrophages: From Mechanisms to Therapy [J].
Noy, Roy ;
Pollard, Jeffrey W. .
IMMUNITY, 2014, 41 (01) :49-61
[82]   Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial [J].
Nywening, Timothy M. ;
Wang-Gillam, Andrea ;
Sanford, Dominic E. ;
Belt, Brian A. ;
Panni, Roheena Z. ;
Cusworth, Brian M. ;
Toriola, Adetunji T. ;
Nieman, Rebecca K. ;
Worley, Lori A. ;
Yano, Motoyo ;
Fowler, Kathryn J. ;
Lockhart, A. Craig ;
Suresh, Rama ;
Tan, Benjamin R. ;
Lim, Kian-Huat ;
Fields, Ryan C. ;
Strasberg, Steven M. ;
Hawkins, William G. ;
DeNardo, David G. ;
Goedegebuure, S. Peter ;
Linehan, David C. .
LANCET ONCOLOGY, 2016, 17 (05) :651-662
[83]  
O'Hara MH, 2021, LANCET ONCOL, V22, P118, DOI 10.1016/S1470-2045(20)30532-5
[84]   Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors [J].
O'Hara, Mark H. ;
Messersmith, Wells ;
Kindler, Hedy ;
Zhang, Wei ;
Pitou, Celine ;
Szpurka, Anna M. ;
Wang, Dan ;
Peng, Sheng-Bin ;
Vangerow, Burkhard ;
Khan, Anis A. ;
Koneru, Mythili ;
Wang-Gillam, Andrea .
JOURNAL OF PANCREATIC CANCER, 2020, 6 (01) :21-31
[85]   TGF-β: Guardian of T Cell Function [J].
Oh, Soyoung A. ;
Li, Ming O. .
JOURNAL OF IMMUNOLOGY, 2013, 191 (08) :3973-3979
[86]   High-Density Gene Expression Analysis of Tumor-Associated Macrophages from Mouse Mammary Tumors [J].
Ojalvo, Laureen S. ;
King, William ;
Cox, Dianne ;
Pollard, Jeffrey W. .
AMERICAN JOURNAL OF PATHOLOGY, 2009, 174 (03) :1048-1064
[87]   An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression [J].
Palazon, Asis ;
Tyrakis, Petros A. ;
Macias, David ;
Velica, Pedro ;
Rundqvist, Helene ;
Fitzpatrick, Susan ;
Vojnovic, Nikola ;
Phan, Anthony T. ;
Loman, Niklas ;
Hedenfalk, Ingrid ;
Hatschek, Thomas ;
Lovrot, John ;
Foukakis, Theodoros ;
Goldrath, Ananda W. ;
Bergh, Jonas ;
Johnson, Randall S. .
CANCER CELL, 2017, 32 (05) :669-+
[88]   Tumor-Associated Macrophages in Tumor Immunity [J].
Pan, Yueyun ;
Yu, Yinda ;
Wang, Xiaojian ;
Zhang, Ting .
FRONTIERS IN IMMUNOLOGY, 2020, 11
[89]   Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies [J].
Panni, Roheena Z. ;
Herndon, John M. ;
Zuo, Chong ;
Hegde, Samarth ;
Hogg, Graham D. ;
Knolhoff, Brett L. ;
Breden, Marcus A. ;
Li, Xiaobo ;
Krisnawan, Varintra E. ;
Khan, Samia Q. ;
Schwarz, Julie K. ;
Rogers, Buck E. ;
Fields, Ryan C. ;
Hawkins, William G. ;
Gupta, Vineet ;
DeNardo, David G. .
SCIENCE TRANSLATIONAL MEDICINE, 2019, 11 (499)
[90]   First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors [J].
Papadopoulos, Kyriakos P. ;
Gluck, Larry ;
Martin, Lainie P. ;
Olszanski, Anthony J. ;
Tolcher, Anthony W. ;
Ngarmchamnanrith, Gataree ;
Rasmussen, Erik ;
Amore, Benny M. ;
Nagorsen, Dirk ;
Hill, John S. ;
Stephenson, Joe, Jr. .
CLINICAL CANCER RESEARCH, 2017, 23 (19) :5703-5710